Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years

BACKGROUND: Type 2 diabetes mellitus is a progressive metabolic disease necessitating therapies with sustained efficacy and safety over time. Exenatide once weekly (ExQW), an extended-release formulation of the glucagon-like peptide-1 receptor agonist exenatide, has demonstrated improvements in glyc...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: MacConell, Leigh, Pencek, Richard, Li, Yan, Maggs, David, Porter, Lisa
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Dove Medical Press 2013
Pynciau:
Original Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC3555554/
https://ncbi.nlm.nih.gov/pubmed/23358123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DMSO.S35801
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg